Research source register

Read the evidence

Sources

Each date identifies a source check. It is separate from this page’s publication date.

  1. WEGOVY — NLM; checked
  2. ZEPBOUND — NLM; checked
  3. SAXENDA — NLM; checked
  4. TRULICITY — NLM; checked
  5. EGRIFTA WR — NLM; checked
  6. VYLEESI — NLM; checked
  7. FDA GLP-1 — FDA; checked
  8. Jastreboff — PubMed; checked
  9. Lau — PubMed; checked
  10. CIR — CIR; checked
  11. Miller — PubMed; checked
  12. FDA cosmetics — FDA; checked
  13. FDA safety — FDA; checked
  14. FDA BPC-157 — FDA; checked
  15. Lee — PubMed; checked
  16. FDA ipamorelin — FDA; checked
  17. Beck — PubMed; checked
  18. Wegovy approval — FDA; checked
  19. Zepbound approval — FDA; checked
  20. Falutz trial — PubMed; checked
  21. Kingsberg trials — PubMed; checked
  22. Wharton — Wiley; checked
  23. Rubino — Wiley; checked
  24. Policy — HHS; checked
  25. Availability notice — Federal Register; checked
  26. Peptides+ preview — Hims & Hers; checked
  27. Drug compounding — FDA; checked

Primary documents used by the finding-care articles below. Provider statements are commercial information, not independently verified clinical outcomes. Individual source dates are retained.

MedCline Wellness review: continuity with one clinician

Legacy Meds review: get the plan and care team in writing

Open Path review: lower session fees, with a separate membership

Psychology Today directory review: look beyond the profile

Use a therapy consultation to ask how care would work

FindTreatment.gov review: a starting point for finding care

Your first teletherapy visit: make room for the conversation

Sesame review: the care subscription behind the GLP-1 price

Hello Alpha review: what the $79 weight-loss membership buys

Livelyhood review: GLP-1 alcohol-craving care, costs and cancellation terms